Exchange Traded Concepts Partners with Loncar
Investments, ISE ETF Ventures, and Amplify Development on the
Loncar Cancer Immunotherapy ETF (NASDAQ: CNCR)
- Cancer immunotherapy companies are
beneficially disrupting cancer treatment by deploying body’s own
immune system to fight disease
- ETF seeks to track index developed by
biotechnology investor Brad Loncar
- ETF offers diversified exposure to both
pharmaceutical companies and clinical-stage biotechnology firms
having immunotherapy focus
The first ETF to exclusively hold shares of public companies
that are engaged in the research and development of therapies that
treat cancer through the body’s immune system will begin trading on
the NASDAQ this morning. The Loncar Cancer Immunotherapy ETF (CNCR)
is based on the Loncar Cancer Immunotherapy Index, an innovative
index developed by biotechnology investor Brad Loncar, and has an
expense ratio of 0.79 percent.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151014005833/en/
Exchange Traded Concepts, LLC (ETC) partnered with Loncar
Investments, ISE ETF Ventures, and Amplify Development LLC on the
successful launch.
The fund includes both large pharmaceutical and growth-oriented
biotechnology companies that are leading this disruptive approach
to cancer treatment. Bristol-Myers Squibb (4.15% index weighting,
ticker: BMY), Merck (3.89% index weighting, ticker: MRK), Juno
Therapeutics (3.53% index weighting, ticker: JUNO) and Cellectis
(2.98% index weighting, ticker: CLLS) are four of the index’s
thirty holdings. Twenty-three of the holdings are growth companies,
while the remaining seven are large-cap, value equities.
“Immunotherapy is changing the way many cancers are being
treated,” said Brad Loncar, Chief Executive Officer of Loncar
Investments. “This innovative field within biotechnology is
expected to become the foundational treatment for cancer over the
next ten years. We think it is important to give investors a
benchmark to track the progress of this growing biotechnology
sector, which over time will likely continue to have a positive
impact on society.”
“The science of cancer immunotherapy is one of the most exciting
areas within biotechnology,” said J. Garrett Stevens, CEO of
Exchange Traded Concepts. “The Loncar Cancer Immunotherapy ETF
allows investors to participate in the breakthrough in this
well-defined sector in a diversified way. We are proud to deliver
this product to the market.”
“We are excited to partner with Exchange Traded Concepts, Loncar
Investments and Amplify Development to bring this new fund to
market,” said Kris Monaco, Head of ISE ETF Ventures. “Our product
portfolio focuses on funds that provide investors with exposure to
targeted segments in first to market ETFs, and the Loncar Cancer
Immunotherapy ETF is an outstanding fit with those objectives.”
“As the ETF market becomes more crowded, it can be challenging
to find new investment themes that tap into a unique and compelling
industry trend,” said Christian Magoon, CEO of Amplify Development
LLC. “With his expertise in the biotechnology space, Brad Loncar
has been able to do exactly that through the Loncar Cancer
Immunotherapy Index, and I am pleased to partner with Brad, ETC and
ISE ETF Ventures to offer this exciting new fund.”
Why immunotherapy: Cancer immunotherapy is an important
sector in biotechnology that is changing the way many cancers are
treated. While traditional medicines like chemotherapies often give
cancer a broad punch, the benefit of using immunotherapy is derived
from the immune system's dynamic nature and the way it can more
precisely be tailored to fight the disease. Some immunotherapies
have exhibited uncommon results in clinical trials including
partial and complete responses in late stage cancer patients.
About Exchange Traded Concepts: ETC is carving out a
niche as a portal to launch new, custom exchange-traded funds
efficiently and cost-effectively through a complete turnkey
solution. ETC is a private-label ETF advisor with passive and
active exemptive relief from the Securities and Exchange Commission
(SEC) to launch both domestic and international equity exchange
traded funds under the Investment Company Act of 1940. For more
information, please go to www.exchangetradedconcepts.com.
About Loncar Investments: Loncar Investments, LLC, the
provider of the Loncar Immunotherapy Index index, is committed to
making the biotechnology space more approachable to a wider range
of investors. The company is principally owned by biotech investor
Brad Loncar. Mr. Loncar manages a biotech-focused family portfolio
from his Lenexa, Kansas office. He can be followed on Twitter
at @bradloncar and his commentary is available at
www.loncarblog.com.
About ISE ETF Ventures: ISE ETF Ventures partners with
issuers to launch exchange traded products (ETPs) such as exchange
traded funds (ETFs), exchange traded notes (ETNs) and other similar
product types. They also provide capital for the start-up and
ongoing backstopping of new ETPs. Partners are able to leverage ISE
ETF Ventures’ global experience and broad network of industry
participants in order to grow their ETP presence and increase
product issuance. Total assets under management for ETPs tied to
ISE ETF Ventures indexes is approximately $3 billion.
ISE ETF Ventures is operated by ISE Holdings, which is a member
of Eurex Group, and together they operate one of the largest
transatlantic derivatives marketplaces. Eurex Group is owned by
Deutsche B�rse AG (Xetra: DB1).
About Amplify Development LLC: Amplify Development LLC is
led by ETF industry veteran Christian Magoon and partners in the
development and support of compelling third party ETFs. The firm is
an affiliate of Amplify Investments LLC, an ETF Sponsor.
Opinions expressed are those of ETC, Loncar Investments and
their partners and are subject to change, not guaranteed, and
should not be considered investment advice.
Investing involves risk; Principal loss is possible. The Fund
will invest in immunotherapy companies which are highly dependent
on the development, procurement and marketing of drugs and the
protection and exploitation of intellectual property rights. A
company's valuation can also be greatly affected if one of its
products is proven or alleged to be unsafe, ineffective or
unprofitable. The costs associated with developing new drugs can be
significant, and the results are unpredictable. The process for
obtaining regulatory approval by the U.S. Food and Drug
Administration or other governmental regulatory authorities is long
and costly and there can be no assurance that the necessary
approvals with be obtained and maintained. The Fund may invest in
foreign securities, which involve political, economic, currency
risk, greater volatility, and differences in accounting methods.
The Fund is non-diversified meaning it may concentrate its assets
in fewer individual holdings than a diversified fund. Therefore,
the Fund is more exposed to individual stock volatility than a
diversified fund. The Fund invests in smaller companies which may
have more limited liquidity and greater volatility compared to
larger companies. The Fund is not actively managed and may be
affected by a general decline in market segments related to the
index. The fund invests in securities included in, or
representative of securities included in, the index, regardless of
their investment merits . The performance of the fund may diverge
from that of the Index and may experience tracking error to a
greater extent than a fund that seeks to replicate an
index.
The Fund's investment objectives, risks, charges and expenses
must be considered carefully before investing. The summary and
statutory prospectuses contain this and other important information
about the investment company, and may be obtained by calling
800.617.0004 or visiting www.loncarfunds.com. Read it carefully
before investing.
Fund holdings are subject to change and should not be considered
a recommendation to buy or sell any security. The % of assets held
in the index and disclosed in this material is as of 10/7/2015. The
ETF, once launched, seeks to replicate the % of holdings in the
underlying index.
The NASDAQ Composite Index is a market capitalization-weighted
index that is designed to represent the performance of the National
Market System which includes over 5,000 stocks traded only
over-the-counter and not on an exchange. One cannot invest directly
in an index.
Diversification does not assure a profit nor protect against
loss in a declining market.
The SEC does not approve or disapprove of any investment.
(www.sec.gov).
The Loncar Cancer Immunotherapy ETF is distributed by Quasar
Distributors, LLC.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151014005833/en/
Media Contact:Joe Anthony for ISE ETF
Venturesise@gregoryfca.com610-228-2095
ETF Series Solutions Tru... (NASDAQ:CNCR)
Historical Stock Chart
From May 2024 to Jun 2024
ETF Series Solutions Tru... (NASDAQ:CNCR)
Historical Stock Chart
From Jun 2023 to Jun 2024